International Journal of Clinical Research
International Journal of Clinical Research. 2023; 7: (7) ; 10.12208/j.ijcr.20230263 .
总浏览量: 343
浙江大学医学院附属第四医院 浙江义乌
浙江大学医学院附属第一医院 浙江杭州
*通讯作者： 杜持新,单位：浙江大学医学院附属第一医院 浙江杭州；
随着化疗、靶向治疗以及造血干细胞移植等治疗手段的增加，白血病患者的生存率不断提高。在疾病发生发展以及治疗过程中眼部并发症也越来越常见，多达90%的患者在确诊或治疗过程中可能出现各种眼部表现。提高眼科医师对于该类疾病眼部受累的认识，将有助于对这类患者的早期诊断及治疗。
With the increase of treatment methods such as chemotherapy, targeted therapy, and hematopoietic stem cell transplantation, the survival rate of patients with leukemia is increasing. And ocular complications are becoming more and more common in the occurrence and development of the disease and the course of treatment. Up to as 90% of patients may have a variety of ocular manifestations in the diagnosis or treatment process. Improving ophthalmologists' understanding of eye involvement in these diseases will contribute to the early diagnosis and treatment of such patients.
[1] Charif Chefchaouni M, Belmekki M, Hajji Z, et al. Ophthalmic manifestations of acute leukemia][J]. J Fr Ophtalmol, 2002, 25(1): 62-6.
[2] Alrobaian M A, Henderson A D. Neuro-Ophthalmic Manifestations of Acute Leukemia[J]. J Neuroophthalmol, 2021, 41(4): e584-e590.
[3] Rosenthal A R. Ocular manifestations of leukemia. A review[J]. Ophthalmology, 1983, 90(8): 899-905.
[4] Sharma T, Grewal J, Gupta S, et al. Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role[J]. Eye (Lond), 2004, 18(7): 663-72.
[5] Duane T D, Osher R H, Green W R. White centered hemorrhages: their significance[J]. Ophthalmology, 1980, 87(1): 66-9.
[6] Tseng M Y, Chen Y C, Lin Y Y, et al. Simultaneous bilateral central retinal vein occlusion as the initial presentation of acute myeloid leukemia[J]. Am J Med Sci, 2010, 339(4): 387-9.
[7] Talcott K E, Garg R J, Garg S J. Ophthalmic manifestations of leukemia[J]. Curr Opin Ophthalmol, 2016, 27(6): 545-551.
[8] Reddy S C, Menon B S. A prospective study of ocular manifestations in childhood acute leukaemia[J]. Acta Ophthalmol Scand, 1998, 76(6): 700-3.
[9] Swartz M, Jampol L M. Comma-shaped venular segments of conjunctiva in chronic granulocytic leukemia[J]. Can J Ophthalmol, 1975, 10(4): 458-61.
[10] Malard F, Mohty M. Acute lymphoblastic leukaemia[J]. Lancet, 2020, 395(10230): 1146-1162.
[11] Estey E, Döhner H. Acute myeloid leukaemia[J]. Lancet, 2006, 368(9550): 1894-907.
[12] Hallek M, Shanafelt T D, Eichhorst B. Chronic lymphocytic leukaemia[J]. Lancet, 2018, 391(10129): 1524-1537.
[13] Bay A, Yilmaz C, Yilmaz N, et al. Vincristine induced cranial polyneuropathy[J]. Indian J Pediatr, 2006, 73(6): 531-3.
[14] Hollander D A, Aldave A J. Drug-induced corneal complications[J]. Curr Opin Ophthalmol, 2004, 15(6): 541-8.
[15] Pavlu J, Czepulkowski B, Kaczmarski R, et al. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib[J]. Lancet Oncol, 2005, 6(2): 128.
[16] Saglio G, Kim D W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia[J]. N Engl J Med, 2010, 362(24): 2251-9.
[17] Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib[J]. Leuk Res, 2008, 32(7): 1022-5.
[18] Basu S, Das T, Biswas G. Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate[J]. Ocul Immunol Inflamm, 2010, 18(1): 64-5.
[19] Radaelli F, Vener C, Ripamonti F, et al. Conjunctival hemorrhagic events associated with imatinib mesylate[J]. Int J Hematol, 2007, 86(5): 390-3.
[20] Moore D C, Muslimani A, Sinclair P. Nilotinib-Induced Ocular Toxicity: A Case Report[J]. Am J Ther, 2018, 25(5): e570-e571.
[21] Filipovich A H, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2005, 11(12): 945-56.
[22] Jagasia M H, Greinix H T, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389-401 e1.
[23] Ogawa Y, Kim S K, Dana R, et al. International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: proposed diagnostic criteria for chronic GVHD (Part I)[J]. Sci Rep, 2013, 3: 3419.
[24] Shikari H, Antin J H, Dana R. Ocular graft-versus-host disease: a review[J]. Surv Ophthalmol, 2013, 58(3): 233-51.
[25] Braun R, Holler E. Acute Ocular Graft-versus-Host Disease[J]. N Engl J Med, 2017, 377(7): 676.